{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,19]],"date-time":"2026-02-19T19:39:40Z","timestamp":1771529980230,"version":"3.50.1"},"reference-count":55,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T00:00:00Z","timestamp":1753488000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"name":"Tanoto Foundation Professorship in Medical Oncology"},{"name":"New Century Foundation Limited"},{"name":"Ling Foundation"},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"crossref","award":["TA21jun-0005"],"award-info":[{"award-number":["TA21jun-0005"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"crossref","award":["CG21APR2002"],"award-info":[{"award-number":["CG21APR2002"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["OFLCG18May-0028"],"award-info":[{"award-number":["OFLCG18May-0028"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001349","name":"National Medical Research Council","doi-asserted-by":"publisher","award":["OFLCG23May-0039"],"award-info":[{"award-number":["OFLCG23May-0039"]}],"id":[{"id":"10.13039\/501100001349","id-type":"DOI","asserted-by":"publisher"}]},{"name":"SingHealth Duke-NUS AM\/ACP-Designated Philanthropic Fund Grant Award","award":["08\/FY2023\/EX\/27-A65"],"award-info":[{"award-number":["08\/FY2023\/EX\/27-A65"]}]},{"name":"Khoo Bridge Funding Award provided by Duke-NUS Medical School and the \u201cEstate of Tan Sri Khoo Teck Puat\u201d.","award":["Duke-NUS-KBrFA\/2025\/0090"],"award-info":[{"award-number":["Duke-NUS-KBrFA\/2025\/0090"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Human Cell"],"abstract":"<jats:title>Abstract<\/jats:title>\n          <jats:p>Anaplastic large-cell lymphoma (ALCL) accounts for 15% of all peripheral T-cell lymphomas globally and can be further divided into subcategories, of which patients with ALK-negative ALCL have dismal prognosis and overall survival. We established a patient-derived xenograft (PDX) and in vitro model (designated PTCL-S1) of <jats:italic>TP63<\/jats:italic>-rearranged ALK-negative ALCL from the primary tumour site of a 55-year old Chinese woman. Whole genome sequencing of the patient\u2019s tumour identified various mutations including <jats:italic>AKT1<\/jats:italic> and <jats:italic>NOTCH1<\/jats:italic>, as well as the <jats:italic>TP63<\/jats:italic>-<jats:italic>TBL1XR1<\/jats:italic> gene fusion. RNA sequencing followed by Sanger sequencing confirmed the gene rearrangement in original tumour, PDX and PTCL-S1 cell line. Immunohistochemistry profiling of the PDX model and cell-line were consistent with the patient\u2019s primary tumour sample (CD3\u2009+\u2009\/CD30\u2009+\u2009\/CD79a-). Cytotoxic agents (doxorubicin, etoposide and gemcitabine) commonly used in ALCL treatment exhibited potent anti-proliferative activity in the cell-line. In conclusion, the established PTCL-S1 cell line can be a useful tool for further investigation of the understanding of <jats:italic>TP63<\/jats:italic>-rearranged ALK-negative ALCL.<\/jats:p>","DOI":"10.1007\/s13577-025-01264-1","type":"journal-article","created":{"date-parts":[[2025,7,26]],"date-time":"2025-07-26T14:17:40Z","timestamp":1753539460000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Establishment and characterization of a novel patient-derived TP63-rearranged anaplastic large-cell lymphoma model PTCL-S1"],"prefix":"10.1007","volume":"38","author":[{"given":"Kelila Xin Ye","family":"Chai","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth Chun Yong","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhimei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nur Ayuni Binte","family":"Muhammad","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jing Quan","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dachuan","family":"Huang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Soon Thye","family":"Lim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4801-3703","authenticated-orcid":false,"given":"Jason Yongsheng","family":"Chan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choon Kiat","family":"Ong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,7,26]]},"reference":[{"key":"1264_CR1","doi-asserted-by":"publisher","first-page":"102793","DOI":"10.1016\/j.ctrv.2024.102793","volume":"129","author":"OA O'Connor","year":"2024","unstructured":"O\u2019Connor OA, Ma H, Chan JYS, Kim SJ, Yoon SE, Kim WS. Peripheral T-cell lymphoma: from biology to practice to the future. Cancer Treat Rev. 2024;129:102793. https:\/\/doi.org\/10.1016\/j.ctrv.2024.102793.","journal-title":"Cancer Treat Rev"},{"issue":"14","key":"1264_CR2","doi-asserted-by":"publisher","first-page":"1068662","DOI":"10.3389\/fimmu.2023.1068662","volume":"26","author":"DRY Yap","year":"2023","unstructured":"Yap DRY, Lim JQ, Huang D, Ong CK, Chan JY. Emerging predictive biomarkers for novel therapeutics in peripheral T-cell and natural killer\/T-cell lymphoma. Front Immunol. 2023;26(14):1068662. https:\/\/doi.org\/10.3389\/fimmu.2023.1068662.","journal-title":"Front Immunol"},{"key":"1264_CR3","doi-asserted-by":"publisher","first-page":"1473","DOI":"10.1182\/blood-2014-04-571091","volume":"124","author":"ER Parrilla Castellar","year":"2014","unstructured":"Parrilla Castellar ER, Jaffe ES, Said JW, et al. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes. Blood. 2014;124:1473\u201380. https:\/\/doi.org\/10.1182\/blood-2014-04-571091.","journal-title":"Blood"},{"issue":"1","key":"1264_CR4","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1186\/s13045-024-01560-7","volume":"17","author":"EWY Chang","year":"2024","unstructured":"Chang EWY, Tan YH, Chan JY. Novel clinical risk stratification and treatment strategies in relapsed\/refractory peripheral T-cell lymphoma. J Hematol Oncol. 2024;17(1):38. https:\/\/doi.org\/10.1186\/s13045-024-01560-7.","journal-title":"J Hematol Oncol"},{"issue":"4","key":"1264_CR5","doi-asserted-by":"publisher","first-page":"554","DOI":"10.1182\/blood-2016-12-755496","volume":"130","author":"MB Pedersen","year":"2017","unstructured":"Pedersen MB, Hamilton-Dutoit SJ, Bendix K, et al. DUSP22 and TP63 rearrangements predict outcome of ALK-negative anaplastic large cell lymphoma: a Danish cohort study. Blood. 2017;130(4):554\u20137. https:\/\/doi.org\/10.1182\/blood-2016-12-755496.","journal-title":"Blood"},{"issue":"9","key":"1264_CR6","doi-asserted-by":"publisher","first-page":"648","DOI":"10.1097\/PAI.0000000000000936","volume":"29","author":"M Parkhi","year":"2021","unstructured":"Parkhi M, Bal A, Das A, et al. ALK-negative anaplastic large cell lymphoma (ALCL): prognostic implications of molecular subtyping and JAK-STAT pathway. Appl Immunohistochem Mol Morphol. 2021;29(9):648\u201356. https:\/\/doi.org\/10.1097\/PAI.0000000000000936. (PMID: 33901030).","journal-title":"Appl Immunohistochem Mol Morphol"},{"issue":"6","key":"1264_CR7","doi-asserted-by":"publisher","first-page":"1590","DOI":"10.3324\/haematol.2022.281442","volume":"108","author":"D Sibon","year":"2023","unstructured":"Sibon D, Bisig B, Bonnet C, et al. ALK-negative anaplastic large cell lymphoma with DUSP22 rearrangement has distinctive disease characteristics with better progression-free survival: a LYSA study. Haematologica. 2023;108(6):1590\u2013603. https:\/\/doi.org\/10.3324\/haematol.2022.281442.","journal-title":"Haematologica"},{"issue":"10168","key":"1264_CR8","doi-asserted-by":"publisher","first-page":"229","DOI":"10.1016\/S0140-6736(18)32984-2","volume":"393","author":"S Horwitz","year":"2019","unstructured":"Horwitz S, O\u2019Connor OA, Pro B, et al. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial. Lancet. 2019;393(10168):229\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(18)32984-2.","journal-title":"Lancet"},{"issue":"1","key":"1264_CR9","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1093\/bioinformatics\/bts635","volume":"29","author":"A Dobin","year":"2013","unstructured":"Dobin A, Davis CA, Schlesinger F, et al. STAR: ultrafast universal RNA-seq aligner. Bioinformatics. 2013;29(1):15\u201321.","journal-title":"Bioinformatics"},{"issue":"1","key":"1264_CR10","doi-asserted-by":"publisher","first-page":"126","DOI":"10.1186\/s13059-020-02043-x","volume":"21","author":"L Tian","year":"2020","unstructured":"Tian L, Li Y, Edmonson MN, et al. CICERO: a versatile method for detecting complex and diverse driver fusions using cancer RNA sequencing data. Genome Biol. 2020;21(1):126. https:\/\/doi.org\/10.1186\/s13059-020-02043-x.","journal-title":"Genome Biol"},{"issue":"17","key":"1264_CR11","doi-asserted-by":"publisher","first-page":"i884","DOI":"10.1093\/bioinformatics\/bty560","volume":"34","author":"S Chen","year":"2018","unstructured":"Chen S, Zhou Y, Chen Y, Gu J. fastp: an ultra-fast all-in-one FASTQ preprocessor. Bioinformatics. 2018;34(17):i884\u201390.","journal-title":"Bioinformatics"},{"key":"1264_CR12","unstructured":"Li H. Aligning sequence reads, clone sequences and assembly contigs with BWA-MEM. q-bioGN. 2013:arXiv:1303.3997v1301."},{"issue":"12","key":"1264_CR13","doi-asserted-by":"publisher","first-page":"2032","DOI":"10.1093\/bioinformatics\/btv098","volume":"31","author":"A Tarasov","year":"2015","unstructured":"Tarasov A, Vilella AJ, Cuppen E, Nijman IJ, Prins P. Sambamba: fast processing of NGS alignment formats. Bioinformatics. 2015;31(12):2032\u20134.","journal-title":"Bioinformatics"},{"issue":"2","key":"1264_CR14","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1093\/bioinformatics\/btv566","volume":"32","author":"K Okonechnikov","year":"2016","unstructured":"Okonechnikov K, Conesa A, Garcia-Alcalde F. Qualimap 2: advanced multi-sample quality control for high-throughput sequencing data. Bioinformatics. 2016;32(2):292\u20134.","journal-title":"Bioinformatics"},{"issue":"7","key":"1264_CR15","doi-asserted-by":"publisher","first-page":"433","DOI":"10.1136\/jmedgenet-2012-100918","volume":"49","author":"X Chang","year":"2012","unstructured":"Chang X, Wang K. wANNOVAR: annotating genetic variants for personal genomes via the web. J Med Genet. 2012;49(7):433\u20136.","journal-title":"J Med Genet"},{"issue":"9","key":"1264_CR16","doi-asserted-by":"publisher","first-page":"1159","DOI":"10.1002\/ajh.26636","volume":"97","author":"JQ Lim","year":"2022","unstructured":"Lim JQ, Huang D, Chan JY, et al. A genomic-augmented multivariate prognostic model for the survival of natural-killer\/T-cell lymphoma patients from an international cohort. Am J Hematol. 2022;97(9):1159\u201369.","journal-title":"Am J Hematol"},{"issue":"8","key":"1264_CR17","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1093\/bioinformatics\/btv710","volume":"32","author":"X Chen","year":"2016","unstructured":"Chen X, Schulz-Trieglaff O, Shaw R, et al. Manta: rapid detection of structural variants and indels for germline and cancer sequencing applications. Bioinformatics. 2016;32(8):1220\u20132.","journal-title":"Bioinformatics"},{"issue":"20","key":"1264_CR18","doi-asserted-by":"publisher","first-page":"3572","DOI":"10.1093\/bioinformatics\/bty304","volume":"34","author":"V Geoffroy","year":"2018","unstructured":"Geoffroy V, Herenger Y, Kress A, et al. AnnotSV: an integrated tool for structural variations annotation. Bioinformatics. 2018;34(20):3572\u20134.","journal-title":"Bioinformatics"},{"key":"1264_CR19","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1182\/blood-2009-06-227579","volume":"115","author":"J Iqbal","year":"2010","unstructured":"Iqbal J, Weisenburger DD, Greiner TC, et al. Molecular signatures to improve diagnosis in peripheral T-cell lymphoma and prognostication in angioimmunoblastic T-cell lymphoma. Blood. 2010;115:1026\u201336. https:\/\/doi.org\/10.1182\/blood-2009-06-227579.","journal-title":"Blood"},{"key":"1264_CR20","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/978-3-319-99716-2_6","volume":"176","author":"A Shustov","year":"2019","unstructured":"Shustov A, Soma L. Anaplastic Large cell lymphoma: contemporary concepts and optimal management. T-Cell NK-Cell Lymphomas. 2019;176:127\u201344. https:\/\/doi.org\/10.1007\/978-3-319-99716-2_6.","journal-title":"T-Cell NK-Cell Lymphomas"},{"key":"1264_CR21","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2020001581","author":"A Shustov","year":"2021","unstructured":"Shustov A, Soma L. ALK-negative anaplastic large cell lymphoma: features and outcomes of 235 patients from the international T-Cell Project. Blood Adv. 2021. https:\/\/doi.org\/10.1182\/bloodadvances.2020001581.","journal-title":"Blood Adv"},{"key":"1264_CR22","doi-asserted-by":"publisher","first-page":"2280","DOI":"10.1182\/blood-2012-03-419937","volume":"120","author":"G Vasmatzis","year":"2012","unstructured":"Vasmatzis G, Johnson SH, Knudson RA, et al. Genome-wide analysis reveals recurrent structural abnormalities of TP63 and other p53-related genes in peripheral T-cell lymphomas. Blood. 2012;120:2280\u20139.","journal-title":"Blood"},{"issue":"3","key":"1264_CR23","doi-asserted-by":"publisher","first-page":"e28","DOI":"10.1111\/bjh.15860","volume":"186","author":"G Hapgood","year":"2019","unstructured":"Hapgood G, Ben-Neriah S, Mottok A, et al. Identification of high-risk DUSP22-rearranged ALK-negative anaplastic large cell lymphoma. Br J Haematol. 2019;186(3):e28\u201331. https:\/\/doi.org\/10.1111\/bjh.15860.","journal-title":"Br J Haematol"},{"key":"1264_CR24","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.humpath.2024.105671","volume":"105671","author":"W Xie","year":"2025","unstructured":"Xie W, Medeiros LJ, Fan G, Li S, Xu J. Systemic ALK-negative anaplastic large cell lymphoma: insights into morphologic, immunophenotypic, genetic and molecular characteristics. Human Pathol. 2025;105671:156. https:\/\/doi.org\/10.1016\/j.humpath.2024.105671.","journal-title":"Human Pathol"},{"issue":"2","key":"1264_CR25","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1111\/his.14674","volume":"81","author":"N Ahmed","year":"2022","unstructured":"Ahmed N, Ketterling RP, Nowakowski GS, Dasari S, Feldman AL. RNAseq identification of FISH-cryptic BCL6::TP63 rearrangement in ALK-negative anaplastic large-cell lymphoma. Histopathology. 2022;81(2):275\u20138.","journal-title":"Histopathology"},{"issue":"10","key":"1264_CR26","doi-asserted-by":"publisher","first-page":"1569","DOI":"10.1038\/sj.leu.2403465","volume":"18","author":"HG Drexler","year":"2004","unstructured":"Drexler HG, MacLeod RA. Malignant hematopoietic cell lines: in vitro models for the study of anaplastic large-cell lymphoma. Leukemia. 2004;18(10):1569\u201371. https:\/\/doi.org\/10.1038\/sj.leu.2403465. (PMID: 15356658).","journal-title":"Leukemia"},{"issue":"23","key":"1264_CR27","first-page":"7682","volume":"50","author":"I Kubonishi","year":"1990","unstructured":"Kubonishi I, Sonobe H, Miyagi T, et al. A Ki-1 (CD30)-positive T (E+, CD4+, Ia+)-cell line, DL-40, established from aggressive large cell lymphoma. Cancer Res. 1990;50(23):7682\u20135 (PMID: 1979248).","journal-title":"Cancer Res"},{"key":"1264_CR28","doi-asserted-by":"publisher","first-page":"2024","DOI":"10.1038\/s41467-018-04356-9","volume":"9","author":"SY Ng","year":"2018","unstructured":"Ng SY, Yoshida N, Christie AL, et al. Targetable vulnerabilities in T- and NK-cell lymphomas identified through preclinical models. Nat Commun. 2018;9:2024. https:\/\/doi.org\/10.1038\/s41467-018-04356-9.","journal-title":"Nat Commun"},{"issue":"6","key":"1264_CR29","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.3324\/haematol.2019.238766","volume":"106","author":"H Larose","year":"2021","unstructured":"Larose H, Prokoph N, Matthews JD, et al. Whole Exome Sequencing reveals NOTCH1 mutations in anaplastic large cell lymphoma and points to Notch both as a key pathway and a potential therapeutic target. Haematologica. 2021;106(6):1693\u2013704. https:\/\/doi.org\/10.3324\/haematol.2019.238766.","journal-title":"Haematologica"},{"issue":"2","key":"1264_CR30","doi-asserted-by":"publisher","first-page":"128","DOI":"10.21037\/atm-20-7574","volume":"9","author":"LH Zhong","year":"2021","unstructured":"Zhong LH, Wu ZD, Wang JC, et al. Molecular profiling of Chinese systemic anaplastic large cell lymphoma patients: novel evidence of genetic heterogeneity. Ann Transl Med. 2021;9(2):128. https:\/\/doi.org\/10.21037\/atm-20-7574.","journal-title":"Ann Transl Med"},{"issue":"4","key":"1264_CR31","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1007\/s13577-024-01077-8","volume":"37","author":"P Sungwan","year":"2024","unstructured":"Sungwan P, Panaampon J, Kariya R, et al. Establishment and characterization of TK-ALCL1: a novel NPM-ALK-positive anaplastic large-cell lymphoma cell line. Hum Cell. 2024;37(4):1215\u201325. https:\/\/doi.org\/10.1007\/s13577-024-01077-8. (Epub 2024 May 16 PMID: 38755432).","journal-title":"Hum Cell"},{"issue":"11","key":"1264_CR32","doi-asserted-by":"publisher","first-page":"3648","DOI":"10.1182\/blood.V84.11.3648.bloodjournal84113648","volume":"84","author":"M Shiota","year":"1994","unstructured":"Shiota M, Fujimoto J, Takenaga M, et al. Diagnosis of t(2;5)(p23;q35)-associated Ki-1 lymphoma with immunohistochemistry. Blood. 1994;84(11):3648\u201352. https:\/\/doi.org\/10.1182\/blood.V84.11.3648.bloodjournal84113648.","journal-title":"Blood"},{"issue":"3","key":"1264_CR33","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1111\/j.1365-2141.2010.08414.x","volume":"152","author":"C Thielen","year":"2011","unstructured":"Thielen C, Bisig B, Gofflot, et al. CHIC cells: a novel ALK+ cell line derived from a relapsed anaplastic large cell lymphoma. Br J Haematol. 2011;152(3):356\u201360. https:\/\/doi.org\/10.1111\/j.1365-2141.2010.08414.x.","journal-title":"Br J Haematol"},{"issue":"10","key":"1264_CR34","doi-asserted-by":"publisher","first-page":"1693","DOI":"10.1038\/sj.leu.2403464","volume":"18","author":"L Lamant","year":"2004","unstructured":"Lamant L, Espinos E, Duplantier M, et al. Establishment of a novel anaplastic large-cell lymphoma-cell line (COST) from a \u201csmall-cell variant\u201d of ALCL. Leukemia. 2004;18(10):1693\u20138. https:\/\/doi.org\/10.1038\/sj.leu.2403464. (PMID: 15356659).","journal-title":"Leukemia"},{"issue":"3","key":"1264_CR35","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1002\/ijc.2910450329","volume":"45","author":"S Barbey","year":"1990","unstructured":"Barbey S, Gogusev J, Mouly H, et al. DEL cell line: a \u201cmalignant histiocytosis\u201d CD30+ t(5;6)(q35;p21) cell line. Int J Cancer. 1990;45(3):546\u201353. https:\/\/doi.org\/10.1002\/ijc.2910450329. (PMID: 2307542).","journal-title":"Int J Cancer"},{"issue":"5\u20136","key":"1264_CR36","doi-asserted-by":"publisher","first-page":"599","DOI":"10.3109\/10428190109097658","volume":"40","author":"I Al-Hashmi","year":"2001","unstructured":"Al-Hashmi I, Decoteau J, Gruss HJ, et al. Establishment of a cytokine-producing anaplastic large-cell lymphoma cell line containing the t(2;5) translocation: potential role of cytokines in clinical manifestations. Leuk Lymphoma. 2001;40(5\u20136):599\u2013611. https:\/\/doi.org\/10.3109\/10428190109097658. (PMID: 11426532).","journal-title":"Leuk Lymphoma"},{"issue":"Suppl. 1","key":"1264_CR37","first-page":"354a","volume":"76","author":"ME Kadin","year":"1990","unstructured":"Kadin ME, Cavaille-Col MW, Sioutos N, et al. Childhood Ki-1+ anaplastic large cell lymphoma: establishment and characterization of a new tumor cell line transplantable to SCID mice. Blood. 1990;76(Suppl. 1):354a\u2013354a.","journal-title":"Blood"},{"issue":"1","key":"1264_CR38","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1182\/blood.V72.1.234.234","volume":"72","author":"P Fischer","year":"1988","unstructured":"Fischer P, Nacheva E, Mason DY, et al. A Ki-1 (CD30)-positive human cell line (Karpas 299) established from a high-grade non-Hodgkin\u2019s lymphoma, showing a 2;5 translocation and rearrangement of the T-cell receptor beta-chain gene. Blood. 1988;72(1):234\u201340 (PMID: 3260522).","journal-title":"Blood"},{"issue":"4","key":"1264_CR39","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1159\/000150340","volume":"36","author":"M Shimakage","year":"1993","unstructured":"Shimakage M, Dezawa T, Tamura S, et al. A Ki-1-positive cell line expressing Epstein-Barr virus antigens, established from a child with Ki-1-positive lymphoma. Intervirology. 1993;36(4):215\u201324. https:\/\/doi.org\/10.1159\/000150340. (PMID: 8169113).","journal-title":"Intervirology"},{"issue":"1","key":"1264_CR40","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1080\/10428190210193","volume":"43","author":"H Merz","year":"2002","unstructured":"Merz H, Lange K, Gaiser T, et al. Characterization of a novel human anaplastic large cell lymphoma cell line tumorigenic in SCID mice. Leuk Lymphoma. 2002;43(1):165\u201372. https:\/\/doi.org\/10.1080\/10428190210193. (PMID: 11908723).","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"1264_CR41","doi-asserted-by":"publisher","first-page":"1851","DOI":"10.1002\/1097-0142(197412)34:6<1851::AID-CNCR2820340602>3.0.CO;2-4","volume":"34","author":"AL Epstein","year":"1974","unstructured":"Epstein AL, Kaplan HS. Biology of the human malignant lymphomas. I. Establishment in continuous cell culture and heterotransplantation of diffuse histiocytic lymphomas. Cancer. 1974;34(6):1851\u201372.","journal-title":"Cancer"},{"issue":"2","key":"1264_CR42","first-page":"192","volume":"132","author":"IJ Su","year":"1988","unstructured":"Su IJ, Balk SP, Kadin ME. Molecular basis for the aberrant expression of T cell antigens in postthymic T cell malignancies. Am J Pathol. 1988;132(2):192\u20138.","journal-title":"Am J Pathol"},{"issue":"8","key":"1264_CR43","doi-asserted-by":"publisher","first-page":"2155","DOI":"10.1182\/blood.V73.8.2155.2155","volume":"73","author":"R Morgan","year":"1989","unstructured":"Morgan R, Smith SD, Hecht BK, et al. Lack of involvement of the c-fms and N-myc genes by chromosomal translocation t(2;5)(p23;q35) common to malignancies with features of so-called malignant histiocytosis. Blood. 1989;73(8):2155\u201364 (PMID: 2525056).","journal-title":"Blood"},{"issue":"5196","key":"1264_CR44","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1126\/science.267.5196.316-b","volume":"267","author":"SW Morris","year":"1995","unstructured":"Morris SW, Kirstein MN, Valentine MB, et al. Fusion of a kinase gene, ALK, to a nucleolar protein gene, NPM, in non-Hodgkin\u2019s lymphoma. Science. 1995;267(5196):316\u20137. https:\/\/doi.org\/10.1126\/science.267.5196.316-b.","journal-title":"Science"},{"issue":"7","key":"1264_CR45","first-page":"1214","volume":"8","author":"A del Mistro","year":"1994","unstructured":"del Mistro A, Leszl A, Bertorelle R, et al. A CD30-positive T cell line established from an aggressive anaplastic large cell lymphoma, originally diagnosed as Hodgkin\u2019s disease. Leukemia. 1994;8(7):1214\u20139 (PMID: 8035614).","journal-title":"Leukemia"},{"issue":"3","key":"1264_CR46","first-page":"439","volume":"135","author":"IJ Su","year":"1989","unstructured":"Su IJ, Kadin ME. Expression of growth factor\/receptor genes in postthymic T cell malignancies. Am J Pathol. 1989;135(3):439\u201345.","journal-title":"Am J Pathol"},{"issue":"7","key":"1264_CR47","doi-asserted-by":"publisher","first-page":"1478","DOI":"10.1002\/cncr.25654","volume":"117","author":"MG Lechner","year":"2011","unstructured":"Lechner MG, Lade S, Liebertz DJ, et al. Breast implant-associated, ALK-negative, T-cell, anaplastic, large-cell lymphoma: establishment and characterization of a model cell line (TLBR-1) for this newly emerging clinical entity. Cancer. 2011;117(7):1478\u201389. https:\/\/doi.org\/10.1002\/cncr.25654.","journal-title":"Cancer"},{"issue":"17","key":"1264_CR48","doi-asserted-by":"publisher","first-page":"4549","DOI":"10.1158\/1078-0432.CCR-12-0101","volume":"18","author":"MG Lechner","year":"2012","unstructured":"Lechner MG, Megiel C, Church CH, et al. Survival signals and targets for therapy in breast implant-associated ALK\u2013anaplastic large cell lymphoma. Clin Cancer Res. 2012;18(17):4549\u201359. https:\/\/doi.org\/10.1158\/1078-0432.CCR-12-0101. (Epub 2012 Jul 12 PMID: 22791880).","journal-title":"Clin Cancer Res"},{"issue":"15","key":"1264_CR49","doi-asserted-by":"publisher","first-page":"3975","DOI":"10.1073\/pnas.1700682114","volume":"114","author":"J Chen","year":"2017","unstructured":"Chen J, Zhang Y, Petrus MN, et al. Cytokine receptor signaling is required for the survival of ALK- anaplastic large cell lymphoma, even in the presence of JAK1\/STAT3 mutations. Proc Natl Acad Sci U S A. 2017;114(15):3975\u201380. https:\/\/doi.org\/10.1073\/pnas.1700682114.","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"6","key":"1264_CR50","doi-asserted-by":"publisher","first-page":"506","DOI":"10.7326\/0003-4819-128-6-199803150-00021","volume":"128","author":"I Kubonishi","year":"1998","unstructured":"Kubonishi I, Machida H, Miyoshi I. Ki-lymphoma and interleukin-6. Ann Intern Med. 1998;128(6):506\u20137. https:\/\/doi.org\/10.7326\/0003-4819-128-6-199803150-00021.","journal-title":"Ann Intern Med"},{"issue":"8","key":"1264_CR51","doi-asserted-by":"publisher","first-page":"2854","DOI":"10.1182\/blood.V94.8.2854.420k07_2854_2861","volume":"94","author":"WP Schiemann","year":"1999","unstructured":"Schiemann WP, Pfeifer WM, Levi E, Kadin ME, Lodish HF. A deletion in the gene for transforming growth factor beta type I receptor abolishes growth regulation by transforming growth factor beta in a cutaneous T-cell lymphoma. Blood. 1999;94(8):2854\u201361 (PMID: 10515889).","journal-title":"Blood"},{"key":"1264_CR52","first-page":"45a","volume":"58","author":"ME Kadin","year":"1988","unstructured":"Kadin ME, Sako D, Morton C, Newcom SR, Su I-J. Characterization of a neoplastic T cell line from a patient with cutaneous T cell lymphoma and regressing T cell skin lesions. Lab Invest. 1988;58:45a\u201345a.","journal-title":"Lab Invest"},{"key":"1264_CR53","first-page":"29a","volume":"50","author":"ME Kadin","year":"1984","unstructured":"Kadin ME, Holt L, Nasu K, Najfeld V. Malignant histiocytosis: establishment and characterization of a neoplastic cell line, MH1. Lab Invest. 1984;50:29a\u201329a.","journal-title":"Lab Invest"},{"issue":"2","key":"1264_CR54","doi-asserted-by":"publisher","first-page":"121","DOI":"10.1007\/BF00356029","volume":"102","author":"D Saltman","year":"1993","unstructured":"Saltman D, Morgan R, Cleary ML, de Lange T. Telomeric structure in cells with chromosome end associations. Chromosoma. 1993;102(2):121\u20138. https:\/\/doi.org\/10.1007\/BF00356029. (PMID: 8432193).","journal-title":"Chromosoma"},{"issue":"6","key":"1264_CR55","doi-asserted-by":"publisher","first-page":"1829","DOI":"10.1182\/blood.V82.6.1829.1829","volume":"82","author":"T Umiel","year":"1993","unstructured":"Umiel T, Rettenmier CW, Siegel S, et al. Establishment and characterization of a human mixed-lineage, T-lymphoid\/myeloid cell line (USP-91). Blood. 1993;82(6):1829\u201337 (PMID: 8400235).","journal-title":"Blood"}],"container-title":["Human Cell"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-025-01264-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s13577-025-01264-1\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s13577-025-01264-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,10]],"date-time":"2025-09-10T03:30:24Z","timestamp":1757475024000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s13577-025-01264-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,26]]},"references-count":55,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["1264"],"URL":"https:\/\/doi.org\/10.1007\/s13577-025-01264-1","relation":{},"ISSN":["1749-0774"],"issn-type":[{"value":"1749-0774","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,26]]},"assertion":[{"value":"12 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interests"}},{"value":"Ethics approval from the SingHealth Centralized Institution Review Board was obtained for tissue collection and consent protocols (CIRB 2018\/3084). Xenograft studies were conducted in compliance with animal protocols approved by the SingHealth Institutional Animal Care and Use Committee (IACUC) (2018\/SHS\/1371).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Written informed consent from the patient for use of clinical data and biospecimens was obtained in accordance with the Declaration of Helsinki.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}],"article-number":"135"}}